Social disparities in the prevalence of diabetes in Australia and in the development of end stage renal disease due to diabetes for Aboriginal and Torres Strait Islanders in Australia and Maori and Pacific Islanders in New Zealand

Kathleen Hill1*, Paul Ward1, Blair S. Grace2 and Jonathan Gleadle3

Abstract

Background: Disparities in health status occur between people with differing socioeconomic status and disadvantaged groups usually have the highest risk exposure and the worst health outcome. We sought to examine the social disparities in the population prevalence of diabetes and in the development of treated end stage renal disease due to type 1 diabetes which has not previously been studied in Australia and New Zealand in isolation from type 2 diabetes.

Methods: This observational study examined the population prevalence of diabetes in a sample of the Australian population (7,434,492) using data from the National Diabetes Services Scheme and of treated end stage renal disease due to diabetes using data from the Australian and New Zealand Dialysis and Transplant Registry. The data were then correlated with the Australian Bureau of Statistics Socioeconomic Indexes for Areas for an examination of socioeconomic disparities.

Results: There is a social gradient in the prevalence of diabetes in Australia with disease incidence decreasing incrementally with increasing affluence (Spearman’s rho = .765 p < 0.001). There is a higher risk of developing end stage renal disease due to type 1 diabetes for males with low socioeconomic status (RR 1.20; CI 1.002–1.459) in comparison to females with low socioeconomic status. In Australia and New Zealand Aboriginal and Torres Strait Islanders, Maori and Pacific Islanders appear to have a low risk of end stage renal disease due to type 1 diabetes but continue to carry a vastly disproportionate burden of end stage renal disease due to type 2 diabetes (RR 6.57 CI 6.04–7.14 & 6.48 CI 6.02–6.97 respectively p < 0.001) in comparison to other Australian and New Zealanders.

Conclusion: Whilst low socioeconomic status is associated with a higher prevalence of diabetes the inverse social gradient seen in this study has not previously been reported. The social disparity seen in relation to treated end stage renal disease due to type 2 diabetes for Aboriginal and Torres Strait Islanders, Maori and Pacific Islanders has changed very little in the past 20 years. Addressing the increasing incidence of diabetes in Australia requires consideration of the underlying social determinants of health.

Keywords: Diabetes, Socioeconomic status, Aboriginal and Torres Strait islanders, Renal disease, Australia, New Zealand
**Background**

Over one million Australians are living with diabetes and 10% of these have type 1 diabetes mellitus (T1DM). The childhood incidence rate of T1DM in Australia (22.5 per 100,000 population) is one of the highest in the world [1] and sits in the top 10 of countries compared across the globe [2]. The population prevalence of type 2 diabetes mellitus (T2DM) in Australia is similar to European countries at 5%, however a higher incidence is seen in New Zealand (7.3%) and has also been demonstrated to be much higher in other countries, for example in Malaysia (17.9%) [3]. Whilst the onset of T2DM is largely attributed to age and obesity with some evidence of predisposing genetic risk [4], the aetiology of T1DM remains unknown. The process through which pancreatic beta cell destruction occurs is autoimmune however it is thought to occur in genetically susceptible individuals and a wide number of hypotheses regarding an environmental trigger have been studied but not yet proven [5]. In Australia a higher prevalence of T2DM is known to be associated with low area socioeconomic status (SES) [6] and potentially related to higher rates of obesity. In contrast to T2DM no association with low area SES has previously been demonstrated for T1DM [7–9]. In Europe, Canada and the United States socioeconomically disadvantaged people have higher rates of morbidity and mortality in T1DM [10–14]. However very little is currently known regarding T1DM prevalence in Australia and the disease outcome of treated end stage renal disease (ESRD) due to T1DM for people with low area SES, this region Indigenous minority populations, Aboriginal and Torres Strait Islanders, and Maori and Pacific Islanders. This study is an exploration of social disparities in diabetes in relation to area SES and Aboriginal and Torres Strait Islander, Maori and Pacific Islander ethnicity.

In 2014, there were 25,626 people in Australia and New Zealand receiving renal replacement therapy for ESRD, and 37% of new cases (n = 954) were attributed to diabetic nephropathy [15]. In this region, people with low area SES are more likely to progress to ESRD due to kidney disease of any aetiology, but this disparity is most pronounced in diabetic nephropathy caused by T2DM [16, 17] with a relative risk of progression to ESRD for the most disadvantaged decile versus the most advantaged decile of 2.38 [17]. While studies from other countries have found a higher likelihood of ESRD due to T1DM for people with low SES [18, 19] this has not previously been studied separately from T2DM in Australia. The incidence of T1DM in the Aboriginal and Torres Strait Islander population is reported to be 9 per 100,000 but this may be an underestimate because of lower levels of registration with the National Diabetes Services Scheme and underreporting of Indigenous status at diagnosis [7]. Although the incidence of T1DM nephropathy has not previously been reported for Aboriginal and Torres Strait Islanders, Maori and Pacific Islanders, the incidence of progression to ESRD from chronic kidney disease in these populations due to any cause is much higher than the general population [20]. It is also known that Aboriginal and Torres Strait Islanders, Maori and Pacific Islanders have a disproportionate burden of ESRD [15] from diabetic nephropathy, which is attributed to a higher prevalence of T2DM but also to an increased likelihood of progressive renal disease [20]. This has largely been attributed to individual behaviours [20] however limited access to appropriate health care services is a strong determinant of health outcomes [21].

**Methods**

**Aims**

The aims of this study were to examine the population prevalence of diabetes in Australia for an association with area SES. This study also sought to determine whether there is any relationship between T1DM ESRD and area SES in Australia, and to re-examine diabetic nephropathy ESRD for this region’s most socially disadvantaged and vulnerable minority populations: Aboriginal and Torres Strait Islanders in Australia, and Maori and Pacific Islanders in New Zealand.

**Study design**

This observational study is a secondary analysis of existing data using an ecological design to make large scale comparisons between groups [22]. Ethical approval for the research was obtained from the Southern Adelaide Clinical Human Research Ethics Committee (SACHREC), reference number 564.13.

**Study period**

This study examined all reported cases of T1DM ESRD for a 5 year period from 2008 to 2012 and the Australian population prevalence of diabetes as recorded in 2014.

**Data sources**

**Treated end stage renal disease**

The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), located within the South Australian Health and Medical Research Institute, record the incidence and outcomes of dialysis and transplant treatment for people with ESRD and receive their data annually from individual Renal units. The information collected by the ANZDATA Registry is used for research that is of benefit to the data contributors, a process overseen by a network of nephrologists, surgeons and renal nurses with interest and expertise in using the data [23]. Australian population data and individual-level de-identified data (gender, age, age of development of ESRD) for all cases of ESRD due to...
Diabetes Services Scheme and the register is thought to diagnose with diabetes register with the National Australian Bureau of Statistics database which listsverted into population prevalence by SEIFA decile using prevalence as a percentage. The data were then con-
verted by the National Diabetes Service Scheme in that postcode (number of people with diabetes) which was recorded, and the population prevalence of diabetes people) in each postcode with a case of T1DM ESRD the Australian population. Population size (number of people) was 17,467 people.

Statistical analysis
The characteristics of the data determined the descriptive and inferential statistics used through an examination of normality, distribution and the level of measurement [26]. For the continuous data, Levine’s tests of normality were used, which have an assumption that the variance between groups is normally distributed. For normally distributed data, the parametric t-test was used for independent variables with two categories, and an analysis of variance (ANOVA) was used for independent variables with more than two categories. Where the continuous dependent variable was not normally distributed and the independent variable had more than two categories, the non-parametric Kruskal–Wallis tests and Spearman’s rank correlation coefficients were used [27, 28]. To calculate the relative risk of T1DM ESRD in relation to area SES the 10 SEIFA deciles were further condensed into two categories of low area SES (deciles 1–5) and high area SES (deciles 6–10). Relative risk estimates were calculated within a chi-squared analysis. Data were analysed in SPSS Statistics for Windows, version 21, IBM Corp., Armonk, NY; IBM Corp 2012.

Results
Prevalence of diabetes mellitus in the population sample (2014)
Population prevalence for any form of diabetes was plotted against the SEIFA deciles.1 The mean prevalence of diabetes was 5.3% (IQR 4.2–6.3, SD 1.63). The prevalence of diabetes in the Australian population varies considerably by SEIFA decile. There was an incremental increase in prevalence as area SES decreased, with the lowest SEIFA decile having a prevalence of diabetes more than double that of the highest decile, demonstrating an inverse social gradient (Fig. 1). The correlation coefficient for association between SEIFA decile and the percentage of the population with diabetes was −.765 (Spearman’s p < 0.001).

Most diabetes cases in Fig. 1 are T2DM (85%) with the remaining 15% comprising of T1DM (12%) and gestational diabetes (3%). The outliers seen in Figs. 1 and 2 were included in the analysis. They represent postcodes (communities) with a much higher or much lower prevalence than that seen in the decile overall and may represent familial clustering or a particularly high density of a single minority ethnic group, both of which are known to be associated with diabetes prevalence.

Prevalence of type 1 diabetes mellitus in the population sample (2014)
In Fig. 2, T1DM data are presented separately to all other types of diabetes. The mean prevalence of T1DM was 0.588% of the population (IQR 0.49–0.66, SD 0.161). The national prevalence of T1DM is known to be 0.5%

The prevalence of diabetes in a sample of the Australian population
This study examined the population prevalence of diabetes in a cross sectional way rather than a whole of region way using the T1DM ESRD post codes as a sample. Using the post codes for each Australian case of ESRD and these post codes were used to explore population prevalence of diabetes to estimate the relative risk of ESRD. The postal areas SEIFA (2011) was used to identify the area SES for each postcode. The population in each post code ranged from 294 to 102,224 however the median population per post code was 17,467 people.

Socioeconomic status
The Socio-Economic Indexes for Areas (SEIFA) is an index developed by the Australian Bureau of Statistics that ranks areas in Australia according to relative socioeconomic advantage based on information from the five-yearly Census [24]. The structure of SEIFA allows measurement of key components of area SES such as income, wealth, social class, occupation, education and community cohesion and individual data from within a post code area is aggregated to rank that post code by area SES. A SEIFA index summarises the characteristics of people and households within an Australian postal area. The combination of these measures allows an integration of the individual, household and community factors that can influence health [25]. Data in SEIFA are ranked in deciles from 1 (lowest area SES) to 10 (highest area SES). ANZDATA records the residential postcode for each Australian case of ESRD and these post codes were used to explore population prevalence of diabetes to estimate the relative risk of ESRD. The postal areas SEIFA (2011) was used to identify the area SES for each postcode. The population in each post code ranged from 294 to 102,224 however the median population per post code was 17,467 people.

The national prevalence of T1DM is known to be 0.5% for a five-year period (n = 534) were obtained from the ANZDATA Registry. Data were also obtained on the relative risk ratio (RR) for T1DM and T2DM ESRD for Aboriginal and Torres Strait Islanders and Maori and Pacific Islanders through an analysis of all data held in the registry.
of the population and previously this has been reported as not being associated with area SES [29]. The results show that population prevalence of T1DM in this study followed a small but statistically significant inverse gradient with higher area SES deciles having an overall lower population prevalence of T1DM (Fig. 2). The correlation coefficient for association between SEIFA decile and the percentage of the population with T1DM was $-0.397$ (Spearman’s $p < 0.001$).

**Type 1 diabetes mellitus treated end stage renal disease**

Incidence rates (new presentations) of T1DM ESRD in Australia are shown in Table 1. Rates have been steadily increasing but there was a much lower incidence for people of Aboriginal and Torres Strait Islander ethnicity. The crude incidence of ESRD due to any cause per million population was 112 [15] with T1DM representing about 4.9% of cases in 2012.

**Age of presentation with type 1 diabetes mellitus and end stage renal disease**

There was an even distribution of age of onset for incident T1DM ESRD cases for both males ($n = 303$) and females ($n = 231$). Table 2 describes the incidence rates of T1DM ESRD during the period studied by age group. The youngest person diagnosed with T1DM ESRD in the period was aged 14 years and the oldest was 81 years. The mean age of presentation was 45 (SD 11.72) and very few cases were diagnosed after the age of 60 years.

Age of onset of ESRD in T1DM did not differ significantly by gender ($p = .612$) however more males developed T1DM ESRD than females (56.3% versus 43.3%). The extremely small number of Aboriginal and

---

**Table 1**

| SEIFA decile | Diabetes % |
|--------------|------------|
| 1            | 7.34       |
| 2            | 6.53       |
| 3            | 6.17       |
| 4            | 6.19       |
| 5            | 5.34       |
| 6            | 5.31       |
| 7            | 5.09       |
| 8            | 4.32       |
| 9            | 4.01       |
| 10           | 3.38       |

**Table 2**

| SEIFA decile | % diabetes |
|--------------|------------|
| 1            | .624       |
| 2            | .637       |
| 3            | .645       |
| 4            | .658       |
| 5            | .597       |
| 6            | .547       |
| 7            | .544       |
| 8            | .520       |
| 10           | .492       |

---

**Fig. 1** Population prevalence (percentage) of any form of diabetes by collation of the sample post codes ranked into SEIFA deciles from 1 (lowest area SES) to 10 (highest area SES) 2014

**Fig. 2** Population prevalence (percentage) of T1DM in Australia by collation of the sample post codes ranked into SEIFA deciles from 1 (lowest area SES) to 10 (highest area SES) 2014
Torres Strait Islanders and Maori seen over this period make a comparison on age of onset between groups unreliable.

**Type 1 diabetes mellitus treated end stage renal disease, socioeconomic status, age and gender**
There were similar numbers of incident cases of T1DM ESRD in each SEIFA decile from the lowest area SES (1) through to 9 (range 43–50) with a slightly smaller number (32) in decile 10, the most advantaged area SES. There was little difference in age of presentation by area SES, with the mean age being almost identical between deciles 1 (47.31) and 10 (47.19). A multivariate one-way ANOVA demonstrated no significant difference between the age of presentation in relation to area SES. There is considerable evidence for poorer outcomes of ESRD regardless of disease aetiology [33] and a bias in propensity to treat towards males [37]. This study has also shown an increased risk of ESRD for males of low area SES. There may be several factors. There is an overall higher incidence of T1DM in males [7], higher cardiac mortality has been demonstrated for females with T1DM [35, 36] resulting in death before the development of ESRD, a higher risk for males of developing ESRD regardless of disease aetiology [33] and a bias in propensity to treat towards males [37]. This study has also shown an increased risk of ESRD for males of low area SES. There is considerable evidence for poorer outcomes in people of low SES with T1DM [10, 14] and of the higher risk of ESRD for males [38, 39], however no other studies to date have found an increased risk of ESRD only for males of low area SES. A recent Swedish study found that being of low SES increased the risk of death two- or three-fold, and that males were more likely to die overall, but this was not explicitly examined in relation to males of low SES [40]. Health care access is an important social determinant of health outcomes in T1DM and Australia offers a Universal 'free' health

### Table 1 T1DM ESRD incidence rates per million population with the lower and upper bound values for the period 2008–2012

| Year | Australia (non-Aboriginal and Torres Strait Islander) | Aboriginal and Torres Strait Islander (Australia) | Maori (NZ) |
|------|------------------------------------------------------|--------------------------------------------------|------------|
| 2008 | 5.90 (4.69–7.34)                                     | 0.26 (0.03–0.95)                                  | 6.22 (1.69–15.93) |
| 2009 | 4.86 (3.77–6.16)                                     | 0.51 (0.14–1.33)                                  | 6.12 (1.66–15.68) |
| 2010 | 5.43 (4.29–6.79)                                     | 0.63 (0.20–1.48)                                  | 3.01 (0.36–10.88) |
| 2011 | 6.50 (5.25–7.96)                                     | 0.12 (0.003–0.69)                                 | 5.93 (1.61–15.20) |
| 2012 | 8.27 (6.85–9.89)                                     | 0.36 (0.07–1.06)                                  | *n/a*      |

*no Maori cases reported for this year

### Table 2 T1DM ESRD new cases for the period 2008–2012 classified by age group

| Age group | Percentage of new cases |
|-----------|-------------------------|
| < 20      | 0.2%                    |
| 21–30     | 10.8%                   |
| 31–40     | 29%                     |
| 41–50     | 30%                     |
| 51–60     | 21%                     |
| > 60      | 9%                      |

Discussion

**Population prevalence of diabetes**
The prevalence of diabetes in the Australian population follows a pronounced inverse social gradient, increasing incrementally as area SES falls. It was previously reported that the national prevalence of diabetes was 5.4% and that low area SES was associated with a threefold higher prevalence of T2DM [6], but the striking and uniform social gradient demonstrated in this study has not been described previously. A recent study in Germany has also demonstrated a social gradient in the prevalence of diabetes [31] suggesting that this may be a global phenomenon. Across the Australian population there was also a statistically significant gradient in T1DM with the highest incidence also seen in the lowest area SES. Although the incidence of T1DM shows a large variation worldwide, environmental or genetic causation has not yet been determined [32] and this is the first Australian study to describe an inverse relationship between incidence of T1DM and area SES.

**Type 1 diabetes mellitus and treated end stage renal disease**
The mean age of presentation with T1DM ESRD (45 years) is significantly lower than for other aetiologies combined (other than paediatric-specific kidney disease) with the national mean age of presentation with ESRD being 60 years [33]. There were few T1DM ESRD cases diagnosed after the age of 60 years, probably because of higher mortality seen in T1DM [34]. There was an excess of ESRD for males with T1DM in Australia and this may be due to several factors. There is an overall higher incidence of T1DM in males [7], higher cardiac mortality has been demonstrated for females with T1DM [35, 36] resulting in death before the development of ESRD, a higher risk for males of developing ESRD regardless of disease aetiology [33] and a bias in propensity to treat towards males [37]. This study has also shown an increased risk of ESRD for males of low area SES. There is considerable evidence for poorer outcomes in people of low SES with T1DM [10, 14] and of the higher risk of ESRD for males [38, 39], however no other studies to date have found an increased risk of ESRD only for males of low area SES. A recent Swedish study found that being of low SES increased the risk of death two- or three-fold, and that males were more likely to die overall, but this was not explicitly examined in relation to males of low SES [40]. Health care access is an important social determinant of health outcomes in T1DM and Australia offers a Universal 'free' health...
care service. However people with low SES have lower levels of health literacy defined as more than literacy and numeracy to incorporate a degree of difficulty in navigating the health care service irrespective of ‘universal coverage’ [41]. Australian research is warranted to explore the higher risk of ESRD for males of low area SES to determine if it is an adverse outcome or in fact a survival advantage.

**Aboriginal and Torres Strait islanders, Maori and Pacific islanders**

The very low incidence of T1DM ESRD in the Aboriginal and Torres Strait Islander and Maori populations, in the face of the extremely high incidence of T2DM ESRD, is difficult to interpret for a number of reasons. The issue of survival may be an underlying factor because there is a well-demonstrated intergenerational cyclical disadvantage experienced by Indigenous people as a result of colonisation [42]. Aboriginal and Torres Strait Islander people have the worst health, lowest life expectancy and highest child mortality rates of all Australians [43] and death rates due to diabetes, which is generally reported as T2DM in this population, are 30 times higher than in other Australians [44]. In addition, there appears to be no studies of young adult onset T1DM in the Aboriginal and Torres Strait Islander population despite Australian data demonstrating that almost 50% of cases of T1DM are diagnosed after the age of 15 years [1, 8]. Studies conducted overseas suggest that up to 30% of cases diagnosed as T2DM test positive for autoantibodies and could be due to T1DM or late onset autoimmune diabetes in adults (LADA) [45]. This raises a second possibility, that of misclassification and conflation of T1DM with T2DM, which could lead to incorrect treatment and earlier death. These findings in relation to T1DM suggest a need to investigate diabetes classification in the Aboriginal and Torres Strait Islander population with autoantibody and C-peptide testing. It is also worth noting that in regard to the grossly inflated risk of ESRD due to T2DM in Aboriginal and Torres Strait Islanders, Maori and Pacific Islanders, these populations also have the lowest SES, and being an ethnic minority and of low SES are independently associated with poor outcomes in diabetes [46].

**Study limitations**

Reporting of census data to the Australian Bureau of Statistics who develop the SEIFA categories is mandatory in Australia. The risk of ecological fallacy is acknowledged when determining individual SES status from area SES through the assumptions that are made about individuals based on group data [47]. However, the purpose of this study is not to determine causation but to make large scale comparisons between groups [22]. The use of SEIFA categories has repeatedly demonstrated that health status is related to socioeconomic status however cannot identify exactly which aspects of socioeconomic disadvantage lead to health disadvantage [48]. In addition there may be status inconsistencies in the SEIFA SES areas. This study reports a sub-sample of the Australian population for diabetes prevalence in relation to SES and a whole of population study would be needed to be fully conclusive. The association between area SES and ESRD could be a consequence of people moving to an area of low SES because of chronic illness and reduced capacity for income. In addition, there are competing risks for ESRD development in relation to the high cardiac mortality seen in T1DM. A diagnosis bias to T2DM for a case of T1DM cannot be excluded when using registry data and there may be inconsistent classification of ethnicity for Aboriginal and Torres Strait Islanders, Maori and Pacific Islanders. Data relating to prevalence and renal outcomes of T1DM in the Aboriginal and Torres Strait Islander, Maori and Pacific Islander population is thought to be widely underreported and insufficient for conclusions to be drawn. The 5 year time frame used in this study is a limitation and may have impacted on the strength of the results. The data in Table 1 describing the incidence of T1DM ESRD would be more fully understood with the addition of standardized rates/reference population however to our knowledge no such data on T1DM is kept in Australia due to the absence of a T1DM registry.

**Conclusion**

This study has demonstrated a uniform inverse social gradient in diabetes prevalence in Australia confirming the strong association between socioeconomic disadvantage and the disease. With regard to diabetic nephropathy ESRD whilst it has previously been demonstrated using ANZDATA that populations in Australia of low area SES carry a heavier burden of ESRD this study of T1DM ESRD over a five-year period shows that there appears to be an increased risk only for males of low area SES. ESRD may not be the most suitable measure of disproportionate outcomes in T1DM in Australia given that a high mortality from the disease for people of low SES before reaching ESRD is likely. Other countries have reported an inverse relationship between SES and mortality in T1DM [10–14] with a much higher likelihood of death for people who are socioeconomically disadvantaged and this disparity is more pronounced in T1DM than in T2DM [49]. For this reason, it remains uncertain whether this study demonstrates an increased risk for males or a survival advantage. While there are doubts about classification of diabetes in the Aboriginal and Torres Strait Islander population, the grossly inflated risk of diabetic nephropathy ESRD for Aboriginal
and Torres Strait Islanders, Maori and Pacific Islanders over the time period studied is a shared disparate outcome across these three minority populations that has changed little in the past 20 years.

Endnotes
1Data are presented in box and whisker plots with outliers (extreme cases in each decile) represented by the symbols °* which denote individual postcodes.

2The postcode with zero prevalence seen in decile 1 (lowest area SES) in Fig. 2 is a remote area and may represent lack of services and/or registration with the National Diabetes Services Scheme.

Abbreviations
ANZDATA: Australia and New Zealand Dialysis and Transplant Registry;
ESRD: End Stage Renal Disease; RR: Relative Risk; SEIFA: Socioeconomic Indexed for Areas; SES: Socioeconomic Status; T1DM: Type 1 Diabetes Mellitus; T2DM: Type 2 Diabetes Mellitus

Acknowledgements
The data reported here have been supplied by the Australia and New Zealand Dialysis and Transplant Registry. The interpretation and reporting of these data are the responsibility of the author and should not be seen as an official policy or interpretation of the Australia and New Zealand Dialysis and Transplant Registry.

The authors acknowledge the contribution of Aarti Gulyani from ANZDATA for assistance with interpretation of the RR of ESRD due to diabetes and in determining the accuracy of the population level data reported. This work within the ANZDATA registry is supported by NHMRC program and capacity building grants.

The authors also thank the patients and the staff of the Renal units in Australia and New Zealand who make these data possible.

Funding
No specific funding was received to conduct this research.

Availability of data and materials
The population data reported in this manuscript is publicly available via the National Diabetes Services Scheme and the Australian Bureau of Statistics. The ESRD data is held by the ANZDATA Registry and subject to a request to access dependent upon ethical approval.

Authors’ contributions
KH prepared the manuscript based on her original research, PW contributed to the design of the study and editing the manuscript, BG contributed to the data analysis and editing the manuscript, JG contributed to the design and editing the manuscript. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate
Ethical approval to conduct this study was obtained from the Southern Adelaide Clinical Human Research Ethics Committee (SACHREC), reference number 564.13.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Discipline of Public Health, Flinders University, Adelaide, South Australia, Australia.
2Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
3School of Medicine, Flinders University, Adelaide, South Australia, Australia.

Received: 27 February 2017 Accepted: 28 September 2017
Published online: 11 October 2017

References
1. Diabetes Australia. 2014. https://www.diabetesaustralia.com.au/.
2. Diabetes UK. 2017. https://www.diabetes.org.uk/.
3. International Diabetes Federation. 2015.
4. Talmud PJ, et al. Sixty-Five Common Genetic Variants and Prediction of Type 2 Diabetes. Diabetes. 2015;64(5):1830–40.
5. Knip M. Pathogenesis of type 1 diabetes: implications for incidence trends. Horm Res Paediatr. 2011;76(Suppl 1):57–64.
6. Australian Institute of Health and Welfare. Cardiovascular disease, diabetes and chronic kidney disease: Australian facts: prevalence and incidence, ISSN ISSN 2204–1397; ISBN 978–1–74249–662–7; Cat. no. CDK 2. 2014.
7. Australian Institute of Health and Welfare: Incidence of type 1 diabetes in Australia 2000–2013 Diabetes series number 23 Cat number CDVD69. Canberra: AIHW.
8. Australian Institute of Health and Welfare: Insulin treated diabetes in Australia 2000-2007 Diabetes series number 11 Cat no CV45. Canberra: AIHW.
9. Evans JMM, et al. Socio-economic status, obesity and prevalence of Type 1 and Type 2 diabetes mellitus. Diabet Med. 2000;17(6):478–80.
10. Austin PC, et al. Income-related differences in mortality among people with diabetes mellitus. Can Med Assoc J. 2010;182(1):E1–17.
11. Burden AC, et al. Psychosocial and socioeconomic risk factors for premature death in young people with type 1 diabetes. Diabetes Care. 2005;28:1618–23.
12. Mühlhauser I, et al. Predictors of mortality and end-stage diabetic complications in patients with Type 1 diabetes mellitus on intensified insulin therapy. Diabet Med. 2000;17(3):727–34.
13. Springer D, et al. Optimal control of type 1 diabetes mellitus in youth receiving intensive treatment. J Pediatr. 2004;144(2):227–32.
14. Dricoll KA, et al. Predictors of study completion and withdrawal in a randomized clinical trial of a pediatric diabetes adherence intervention. Contemp Clin Trials. 2009;30(3):212–20.
15. Australia and New Zealand Dialysis and Transplant Registry, 37th Annual report. 2014: Adelaide. ISSN 1329-2870.
16. Grace BS, et al. Socio-economic status and incidence of renal replacement therapy: a registry study of Australian patients. Nephrol Dial Transplant. 2012;27(1):1473–80.
17. Grace BS, Clayton P, McDonald SP. Increases in renal replacement therapy in Australia and New Zealand: Understanding trends in diabetic nephropathy. Nephrology. 2012;17(1):76–84.
18. Secret A, et al. Association between socioeconomic status and major complications in type 1 diabetes: the Pittsburgh epidemiology of diabetes complications (EDC) study. Ann Epidemiol. 2011;21:375–8.
19. Walsh MG, et al. The socioeconomic correlates of global complication prevalence in type 1 diabetes (T1D): A multinational comparison. Diabetes Res Clin Pract. 2005;70(2):143–50.
20. Stewart JH, McCredi ME, McDonald SP. The incidence of treated end-stage renal disease in New Zealand Maori and Pacific Island people and in Indigenous Australians. Nephrol Dial Transplant. 2004;19(3):678–85.
21. Cass A, et al. Exploring the pathways leading from disadvantage to end-stage renal disease in Indigenous Australians. Soc Sci Med. 2004;58(8):1767–85.
22. Sedgwick P. The ecological fallacy. Br Med J. 2011;343:d4670.
23. McDonald SP, Russ GR. Australian registries—ANZDATA and ANZOD. Transplant Rev. 2013;27(2):46–9.
24. Australian Bureau of Statistics. National statistical service. 2014. http://www.abs.gov.au/.
25. Calixto OJ, Anaya JM. Socioeconomic status. The relationship with health and autoimmune diseases. Autoimmun Rev. 2014;13(6):641–54.
26. Lianputtong, P., Research methods in health - foundations for evidence based practice. 2013, Melbourne, Australia: Oxford University Press.
27. Pallant, J., SPSS survival manual - a step by step guide to data analysis using IBM SPSS. 5th edition ed. 2013, Crows Nest, NSW: Allen & Unwin.
28. Green, S.B.S., N J, Using SPSS for Windows and Macintosh. Fourth Edition ed. 2005, New Jersey: Pearson Prentice Hall.
29. Australian Institute of Health and Welfare. Incidence of type 1 diabetes in Australia 2000–2013 (AIHW). 2015.
30. Australia and New Zealand Dialysis and Transplant Registry, Odds ratio T1DM and T2DM. South Australia: ANZDATA; 2014.
31. Grundmann N, et al. Area deprivation and the prevalence of type 2 diabetes and obesity: analysis at the municipality level in Germany. BMC Public Health. 2014;14(1):1–8.
32. Jianguang J, et al. Ethnic Differences in Incidence of Type 1 Diabetes Among Second Generation Immigrants and Adoptees from Abroad. J Clin Endocrinol Metab. 2010;95(2):847–50.
33. McDonald S, Clayton P, Hurst K. Australia and New Zealand Dialysis and Transplant Registry, 35th Annual report. South Australia: ANZDATA; 2012.
34. Huo L, et al. Life expectancy of type 1 diabetic patients during 1997–2010: a national Australian registry-based cohort study. Diabetologia. 2016;1–9. doi:10.1007/s00125-015-3857-4.
35. Huxley R, et al. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3:198–206.
36. Cooper MN, et al. Clinical and demographic risk factors associated with mortality during early adulthood in a population-based cohort of childhood-onset Type 1 diabetes. Diabet Med. 2014;31(12):1550–8.
37. Hecking M, Bieber BA, Ether J, Kautzky-Willer A, Sunder-Plasmann G, Sailer M, Ramirez SP, Gillespie BW, Pisoni RL, Robinson BM, Friedrich K. Port Sex-Specific Differences in Hemodialysis Prevalence and Practices and the Male-to-Female Mortality Rate: The Dialysis Outcomes and Practice Patterns Study (DOPPS). PLoS Med. 2014;11(10):e1001750.
38. Möllsten A, et al. Cumulative risk, age at onset, and sex-specific differences for developing End-Stage Renal Disease in young patients with type 1 diabetes: A nationwide population-based cohort study. Diabetes. 2010;59(7):1803–8.
39. Rawshani A, et al. Impact of Socioeconomic Status on Cardiovascular Disease and Mortality in 24,947 Individuals With Type 1 Diabetes. Diabetes Care. 2015;38(10):2523–8.
40. Cavanaugh K, Kripalani S, Osborn CY. Strategies to address low health literacy and numeracy in diabetes. Clinical Diabetes. 2010;28:171+.
41. Reid, J., K. Taylor-Moore, and G. Varona, Towards a social-structural model for understanding current disparities in Māori health and wellbeing. Journal of Loss and Trauma, 2013: p. https://doi.org/10.1080/15325024.2013.809295.
42. Baum, F.E., The New Public Health. Vol. Third Edition. 2008, Melbourne, Australia: Oxford University Press.
43. Cunningham J, et al. Study protocol—diabetes and related conditions in urban indigenous people in the Darwin, Australia region: aims, methods and participation in the DRUID Study. BMC Public Health. 2006;6:8.
44. Unger J. Latent Autoimmune Diabetes in Adults. Am Fam Physician. 2010;81(7):843–7.
45. Carter P.J, et al. Ethnicity and social deprivation independently influence metabolic control in children with type 1 diabetes. Diabetologia. 2008;51(10):1835–42.
46. Winzar H. The ecological fallacy: How to spot one and tips on how to use one to your advantage. Australas Mark J AMJ. 2015;23(1):86–92.
47. McCracken K. Into a SEIFA SES cul-de-sac? Aust N Z J Public Health. 2001;25(4):305–6.
48. Forssas E, et al. Socio-economic predictors of mortality among diabetic people. Eur J Pub Health. 2012;22(3):305–10.